Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
OHSU Knight Cancer Institute
Incyte Corporation
NGM Biopharmaceuticals, Inc
Eli Lilly and Company
National Cancer Institute (NCI)
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
Altor BioScience
Dartmouth-Hitchcock Medical Center
Case Comprehensive Cancer Center
Herlev Hospital